1. Home
  2. ASPI vs RLMD Comparison

ASPI vs RLMD Comparison

Compare ASPI & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ASP Isotopes Inc.

ASPI

ASP Isotopes Inc.

HOLD

Current Price

$4.04

Market Cap

475.3M

Sector

Industrials

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$5.38

Market Cap

524.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASPI
RLMD
Founded
2021
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
475.3M
524.9M
IPO Year
2022
2012

Fundamental Metrics

Financial Performance
Metric
ASPI
RLMD
Price
$4.04
$5.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$12.00
$12.40
AVG Volume (30 Days)
4.0M
1.6M
Earning Date
04-10-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.28
EPS
N/A
N/A
Revenue
$23,849,000.00
$13,070.00
Revenue This Year
$68.41
N/A
Revenue Next Year
$126.69
N/A
P/E Ratio
N/A
N/A
Revenue Growth
475.48
154.83
52 Week Low
$3.51
$0.55
52 Week High
$14.49
$8.00

Technical Indicators

Market Signals
Indicator
ASPI
RLMD
Relative Strength Index (RSI) 38.29 35.17
Support Level $3.86 $4.85
Resistance Level $5.88 $7.28
Average True Range (ATR) 0.32 0.39
MACD 0.02 -0.01
Stochastic Oscillator 30.40 13.01

Price Performance

Historical Comparison
ASPI
RLMD

About ASPI ASP Isotopes Inc.

ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Currently, the company has three operating segments: (i) nuclear fuels, (ii) specialist isotopes and related services, and (iii) construction services. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: